BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

BALA CYNWYD, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Hawaiian Holdings, Inc. (Nasdaq – HA)

Under the terms of the agreement, Hawaiian Airlines will be acquired by Alaska Air Group, Inc. (NYSE - ALK). Hawaiian Airlines stockholders will receive $18.00 in cash for each share of the Company’s stock for a transaction value of approximately $1.9 billion, inclusive of $0.9 billion of Hawaiian Airlines net debt. The investigation concerns whether the Hawaiian Airlines Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Alaska Air is paying fair value to shareholders of the Company.

Additional information can be found at https://www.brodskysmith.com/cases/hawaiian-holdings-inc-nasdaq-ha/ .

ImmunoGen, Inc. (Nasdaq – IMGN)

Under the terms of the agreement, ImmunoGen will be acquired by AbbVie Inc. (NYSE - ABBV). AbbVie will acquire all outstanding shares of ImmunoGen for $31.26 per share in cash. The transaction values ImmunoGen at a total equity value of approximately $10.1 billion. The investigation concerns whether the ImmunoGen Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether AbbVie is paying fair value to shareholders of the Company.

Additional information can be found at https://www.brodskysmith.com/cases/immunogen-inc-nasdaq-imgn/.

Graphite Bio, Inc. (Nasdaq – GRPH)

Under the terms of the agreement, Graphite Bio will merge with LENZ Therapeutics in an all-stock transaction. Under the terms of the merger agreement, securityholders of LENZ Therapeutics will own approximately 65% of the combined company and securityholders of Graphite Bio will own approximately 35% of the combined company. The investigation concerns whether the Graphite Bio Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of the Company’s shareholders in the combined company.

Additional information can be found at https://www.brodskysmith.com/cases/graphite-bio-inc-nasdaq-grph/.

CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

Under the terms of the Merger Agreement, CapStar will be acquired by Old National Bancorp (“Old National”) (Nasdaq – ONB) in an all-stock transaction. Each outstanding share of CapStar common stock will be converted into the right to receive 1.155 shares of Old National common stock, valuing the transaction at approximately $344.4 million, or $16.64 per share, based on Old National’s 30-day volume weighted average closing stock price ending October 25, 2023. The investigation concerns whether the CapStar Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Old National is paying fair value to shareholders of the Company. For example, the deal consideration is below the 52-week high of $18.52 for the Company’s shares.

Additional information can be found at https://www.brodskysmith.com/cases/capstar-financial-holdings-inc-nasdaq-cstr/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.